Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IMpower131

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Combination increases complete response rate to 24% compared to chemotherapy alone

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk

REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial

Roche Basel Switzerland

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

First SMA treatment approved in the EU that can be taken at home

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Phase 3 trial is evaluating the therapy in high-risk non-hospitalised patients with COVID-19

Roche Basel Switzerland

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

- PMLiVE

Roche buys GenMark for $1.8bn to bolster diagnostics portfolio

Swiss pharma company will gain respiratory pathogen panels to strengthen its COVID-19 testing capabilities

- PMLiVE

FDA advisory committee to review oncology accelerated approvals

Review comes after voluntary indication withdrawals for a number of cancer therapies

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links